Small Bowel Cancer

  • David Gleason
  • Kimberly E. Miller-Hammond
  • John F. Gibbs


Small bowel cancers comprise a rare group of neoplasms that account for 1–5 % of all gastrointestinal cancers. These cancers include adenocarcinoma, carcinoid, lymphoma, gastrointestinal stromal tumors (GISTs), sarcomas, and other neoplasms. They share a common characteristic, mainly that they all have a poor overall survival (OS) because of the delay in diagnosis. The mainstay of treatment is surgical resection of the primary tumor, but due to the indolent nature of symptoms, many tumors are widespread at the time of presentation. There have been improvements in both invasive and noninvasive diagnostic studies for small bowel cancers. Capsule endoscopy and double-balloon enteroscopy have offered the clinician a complete evaluation of the small intestine not previously available. OS has improved with better chemotherapy for GISTs and lymphoma, but effective chemotherapy for adenocarcinoma remains elusive.


Small Bowel Neuroendocrine Tumor Familial Adenomatous Polyposis Carcinoid Tumor Gastrointestinal Stromal Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    American Cancer Society Facts and Figures 2013. Atlanta. Accessed on 13 May 2014.
  2. 2.
    Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States. Ann Surg 2009;249(1): 63–71.Google Scholar
  3. 3.
    Speranza G, Doroshow JH, Kummar S. Adenocarcinoma of the small bowel: changes in the landscape? Curr Opin Oncol. 2010;22:387–93.PubMedCrossRefGoogle Scholar
  4. 4.
    Cheung DY, Choi MG. Current advances in small bowel tumors. Clin Endosc. 2011;44:13–21.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Anzidei M, Napoli A, Zini C, Kirchin MA, Catalano C, Passariello R. Malignant tumours of the small intestine: a review of histopathology, multidetector CT and MRI aspects. Br J Radiol. 2011;84:677–90.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Agrawal S, McCarron EC, Gibbs JF, Nava HR, Wilding GE, Rajput A. Surgical management and outcome in primary adenocarcinoma of the small bowel. Ann Surg Oncol. 2007;14(8):2263–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Kopacova M, Rejchrt S, Bures J, Tacheci I. Small Intestinal Tumours. Gastroenterol Res Pract; 2013; 2013: 702536. doi:  10.1155/2013/702536
  8. 8.
    Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well differentiated endocrine tumors. J Clin Oncol. 2008;26(6):963–70.PubMedCrossRefGoogle Scholar
  9. 9.
    Balon HR, Brown TLY, Goldsmith SJ, Silberstein EB, Krenning EP, Lang O, Dillehay GD, Tarrance J, Johnson M, Stabin MG. The SNM practice guideline for somatostatin receptor scintigraphy with in-111-pentetreotide. Version 2.0. J Nucl Med Technol. 2011;39(4):317–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Neuroendocrine Tumors. NCCN guidelines Version 2.2014 Accessed on 13 May 2014.
  11. 11.
    Kobara H, Mori H, Kazi R, Fujihara S, Nishiyama N, Ayaki M, Yachida T, Tani J, Miyoshi H, Kamada H, Morishita A, Oryu M, Tsutsui K, Haba R, Masaki T. Indications for endoscopic submucosal dissection for symptomatic benign gastrointestinal subepithelial or carcinoid tumors originating in the submucosa. Mol Clin Oncol. 2013;1:1002–8.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Strosberg JR, Fisher GA, Benson AB, Malin JL, GEPNET consensus panel, Cherepanov D, Broder MS. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors. Pancreas. 2013;42(3):397–404.PubMedCrossRefGoogle Scholar
  13. 13.
    Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16:885–94.PubMedCrossRefGoogle Scholar
  14. 14.
    Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol. 2012;23(7):124–30.Google Scholar
  15. 15.
    Araujo PB, Cheng S, Mete O, Serra S, Morin E, Asa S, Ezzat S. Evaluation of the WHO 2010 grading and AJCC/UICC staging systems in prognostic behavior of intestinal neuroendocrine tumors. PLoS One. 2013;8(4):e61538. doi: 10.1371/journal.pone.0061538.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Gibbs J. Duodenal adenocarcinoma: is total lymph node sampling predictive of outcome? Ann Surg Oncol. 2004;11(4):354–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Moon YW, Rha SY, Shin SJ, Chang J, Shim HS, Roh JK. Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. J Cancer Res Clin Oncol. 2010;136(3):387–94.PubMedCrossRefGoogle Scholar
  18. 18.
    Halfdanarson TR, McWillliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg Oncol. 2007;14(8):797–803.Google Scholar
  19. 19.
    Ojha A. Primary small bowel malignancies: single center results of three decades. J Clin Gastroenterol. 2000;30(3):289–93.PubMedCrossRefGoogle Scholar
  20. 20.
    Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestines. Acta Oncol. 2010;49(4):474–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Chung WC, Paik CN, Jung SH. Prognostic factors associated with survival in patients with primary duodenal adenocarcinoma. Korean J Intern Med. 2011;26(1):34–40.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Chaiyasate K. Prognostic factors in primary adenocarcinoma of the small intestine: 13 year single institution experience. World J Surg Oncol. 2008;6(1):12.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Kelsey CR, Nelson JW, Willett CG. Duodenal adenocarcinoma: patterns of failure after resection and role of chemotherapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1436–41.PubMedCrossRefGoogle Scholar
  24. 24.
    Fishman PN, Pond GR, Moore MJ. Natural history of chemotherapy effectiveness for advanced adenocarcinoma of the small bowel; a retrospective review of 113 cases. Am J Clin Oncol. 2006;29(3):225–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Overman MJ, Varadhachary GR, Kopetz S. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27(16):2598–603.PubMedCrossRefGoogle Scholar
  26. 26.
    Koo DH, Yun SC, Hong YS, Ryu MH, Lee JL, Chang HM, Kang YK, Kim SC, Han DJ, Lee YJ, Kim TW. Adjuvant chemotherapy for small bowel adenocarcinoma after curative surgery. Oncology. 2011;80(3–4):208–13.PubMedCrossRefGoogle Scholar
  27. 27.
    North JH, Pack MS. Malignant tumors of the small intestine: a review of 144 cases. Am Surg. 2000;66(1):46–51.PubMedGoogle Scholar
  28. 28.
    Hong SH, Koh YH, Rho SY, Byun JH, Oh ST, Im KW, Kim EK, Chang SK. Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome. Jpn J Clin Oncol. 2009;39(1):54–61.PubMedCrossRefGoogle Scholar
  29. 29.
    Zaanan A, Costes L, Gauthier M, Malka M, Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, Moulin V, Afchain P, Taieb J, Bonnetain F, Aparicio T. Chemotherapy of advanced small bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol. 2010;21:1786–93.PubMedCrossRefGoogle Scholar
  30. 30.
    DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor. ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258(3):46–52.CrossRefGoogle Scholar
  31. 31.
    Alassas M, Ong ES, Kane JM, Gibbs J. Duodenal gastrointestinal stromal tumors: a diagnostic and surgical challenge. Ann Surg. 2008;15:SK2.Google Scholar
  32. 32.
    DeMatteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF, Antonescu CR. Tumor mitotic rate, size, and location independently predict recurrence after resection or primary gastrointestinal stromal tumor. Cancer. 2008;112:608–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Bautista-Quach MA, Ake CD, Chen M, Wang J. Gastrointestinal lymphomas: morphology, immunophenotype and molecular features. J Gastrointest Oncol. 2012;3(3):209–25.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Compton C, Byrd D, Garcia-Aguilar J, et al. Small Intestine. In: Compton C, Byrd D, Garcia-Aguilar J, Kurtzman S, Olawaiye A, Washington M, editors. AJCC cancer staging atlas. 2nd ed. New York: Springer; 2012. p. 155–67.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • David Gleason
    • 1
  • Kimberly E. Miller-Hammond
    • 1
  • John F. Gibbs
    • 2
  1. 1.Department of Surgery, Kaleida Health/Buffalo General Medical CenterState University of New York at BuffaloBuffaloUSA
  2. 2.Department of SurgeryJersey Shore University Medical Center/Meridian HeathNeptuneUSA

Personalised recommendations